Publication | Closed Access

Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib

Breast OncologyBreast Tumor ProgressionMedicineBreast CancerCancer BiologyBtg2 ExpressionErbb/her Inhibitor LapatinibCancer TreatmentAnti-cancer AgentRadiation OncologyOncologyCell BiologyTumor Biology